• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Nutex Health Inc.

    6/3/25 5:20:57 PM ET
    $NUTX
    Business Services
    Consumer Discretionary
    Get the next $NUTX alert in real time by email
    DEFA14A 1 nutx-20250603xdefa14a.htm DEFA14A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    (Amendment No.         )

    Filed by the Registrant ☒

    Filed by a party other than the Registrant ☐

    Check the appropriate box:

    ☐Preliminary Proxy Statement

    ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐Definitive Proxy Statement

    ☒Definitive Additional Materials

    ☐Soliciting Material Under §240.14a-12

    Nutex Health Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

    ☒

    No fee required

    ☐

    Fee paid previously with preliminary materials

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

    ​

    ​


    SUPPLEMENT DATED JUNE 3, 2025 TO
    PROXY STATEMENT DATED JUNE 2, 2025

    This document is a supplement dated June 3, 2025 (the “Supplement”) to the proxy statement dated June 2, 2025 and first mailed to stockholders of Nutex Health Inc. (the “Company”) on or about June 2, 2025 (the “Proxy Statement”) in connection with its annual meeting (as the same may be adjourned or postponed, the “Annual Meeting”) of common stockholders of the Company which will be held on July 14, 2025 at 10:00 a.m., Central Time for the following purposes:

    ​

    1.To re-elect the following members of our Board of Directors:

    Thomas T. Vo, Warren Hosseinion, Cheryl Grenas, Michael L. Reed, Scott J. Saunders and Kelvin Spears; and to elect Frank E. Jaumot as a new member of our Board of Directors;

    each to serve as directors and to hold office for a one-year term to expire at the 2026 annual meeting of stockholders or in the case of their resignation or removal, until their successors are duly elected and qualified;

    2.To vote in an advisory capacity concerning the Company’s executive compensation;

    ​

    3.To approve an amendment to the Amended and Restated Nutex Health Inc. 2023 Equity Incentive Plan (the “Plan”) to increase the number of shares available for issuance under the Plan by 1,100,000 and to allow the number of shares available for issuance under the Plan to automatically increase on January 1 of each year, in an amount equal to 5% of the number of shares outstanding at December 31 of the previous fiscal year, provided that the Board may decide that there shall be no or a lesser increase;

    ​

    4.To ratify the appointment of Grant Thornton LLP as our independent registered public accounting firm for the year ending December 31, 2025; and

    ​

    5.To consider and vote upon such other business as may be properly brought before the Annual Meeting or any adjournments or postponements thereof.

    ​

    INTRODUCTION AND EXPLANATORY NOTE

    Capitalized terms used herein, but not otherwise defined, shall have the meanings ascribed to such terms in the Proxy Statement. Except as described in this Supplement, the information provided in the Proxy Statement continues to apply. This Supplement and the documents referred to in this Supplement should be read in conjunction with the Proxy Statement, and the documents referred to in the Proxy Statement, each of which should be read in its entirety. To the extent that information in this Supplement differs from, updates, or conflicts with information contained in the Proxy Statement, the information in this Supplement supersedes the information in the Proxy Statement.

    This Supplement should be read in conjunction with the Proxy Statement and the Proxy Statement should be read in its entirety. The purpose of this Supplement is to amend the Proxy Statement to correct typographical errors (the “Supplemental Disclosures”). Except as described in this Supplement, the information provided in the Proxy Statement is not amended, supplemented, or otherwise modified.

    ​

    ​

    ​


    SUPPLEMENTAL DISCLOSURES

    All paragraph headings and page references refer to the headings and pages in the Proxy Statement before any additions or deletions resulting from the Supplemental Disclosures or any other amendments. Where applicable, the Supplemental Disclosures are identified below by underlined text. Stricken through text shows text being deleted from a referenced disclosure in the Proxy Statement.

    Amendment to the 2023 Equity Incentive Plan

    To conform to the disclosure contained under “What vote is required to approve each matter and how are votes counted?” on page 7 of the Proxy Statement, the Section entitled “Vote Required for Approval” on page 31 of the Proxy Statement with respect to the Company’s Proposal 3: Amendment to the 2023 Equity Incentive Plan is hereby amended and supplemented as follows:

    The approval of the Amendment Proposal requires the affirmative vote (in person or by proxy) of the holders of a majority of the outstanding shares of our Common Stock entitled to vote and actually cast thereon at the Annual Meeting. Failure to vote by proxy or to vote in person or an abstention from voting will have no effect on the outcome of the vote on the Amendment Proposal. Abstentions and broker non-votes will have the same effect as votes against no impact on the vote on this proposal.


    Get the next $NUTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NUTX

    DatePrice TargetRatingAnalyst
    11/12/2024$45.00 → $50.00Buy
    Maxim Group
    9/18/2024$45.00Buy
    Maxim Group
    2/22/2023$3.00Outperform
    Northland Capital
    More analyst ratings

    $NUTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NUTEX HEALTH ANNOUNCES INTERNET AVAILABILITY OF PROXY MATERIALS FOR ITS 2025 ANNUAL MEETING

      HOUSTON, June 2, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks, today announced the availability of its definitive proxy materials for its 2025 annual meeting to be held on July 14, 2025 at 10:00 am Central Time via the internet as a virtual meeting only (and not in person) at www.virtualshareholdermeeting.com/NUTX2025. We look forward to hosting you at our virtual shareholder meeting and encourage you to participate and vote. Commenc

      6/2/25 10:18:00 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF GRANT THORNTON LLP AS ITS INDEPENDENT AUDITOR

      HOUSTON, May 22, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Grant Thornton LLP ("Grant Thornton") as the Company's independent registered public accounting firm to replace CBIZ CPAs ("CBIZ"), effective May 15, 2025. The change of the Company's independent auditor was made after careful consideration and an evaluation process and was approved by the Audit Committee and the Board of Directors of the

      5/22/25 6:30:00 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • NUTEX HEALTH REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

      TOTAL REVENUE OF $211.8 MILLION VERSUS $67.5 MILLION IN Q1 2024, AN INCREASE OF 213.8%NET INCOME ATTRIBUTABLE TO NUTEX HEALTH INC. OF $14.6 MILLION VERSUS NET LOSS OF $0.4 MILLION IN Q1 2024DILUTED EPS OF $2.56 PER SHARE VERSUS $(0.08) PER SHARE IN Q1 2024EBITDA OF $43.1 MILLION VERSUS $7.1 MILLION IN EBITDA IN Q1 2024, AN INCREASE OF 507.0%ADJUSTED EBITDA OF $72.8 MILLION VERSUS $(0.4) MILLION IN Q1 2024NET CASH FROM OPERATING ACTIVITIES OF $51.0 MILLIONCOMPANY BELIEVES ITS ARBITRATION EFFORTS THROUGH THE INDEPENDENT DISPUTE RESOLUTION (IDR) PROCESS HAVE RESULTED IN MORE FAIR AND REASONABLE PAYMENTSHOUSTON, May 13, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NA

      5/13/25 5:43:00 PM ET
      $NUTX
      Business Services
      Consumer Discretionary

    $NUTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Bates Jon Christian converted options into 1,611 shares and bought $81,810 worth of shares (1,000 units at $81.81), increasing direct ownership by 115% to 4,888 units (SEC Form 4)

      4 - Nutex Health, Inc. (0001479681) (Issuer)

      4/14/25 4:30:48 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Director Spears Kelvin converted options into 143 shares and covered exercise/tax liability with 34 shares, increasing direct ownership by 0.34% to 31,992 units (SEC Form 4)

      4 - Nutex Health, Inc. (0001479681) (Issuer)

      4/14/25 4:15:36 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Chief Operating Officer Detillio Joshua converted options into 2,125 shares and covered exercise/tax liability with 452 shares, increasing direct ownership by 35% to 6,481 units (SEC Form 4)

      4 - Nutex Health, Inc. (0001479681) (Issuer)

      4/14/25 4:01:59 PM ET
      $NUTX
      Business Services
      Consumer Discretionary

    $NUTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group reiterated coverage on Nutex Health with a new price target

      Maxim Group reiterated coverage of Nutex Health with a rating of Buy and set a new price target of $50.00 from $45.00 previously

      11/12/24 8:15:57 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Maxim Group initiated coverage on Nutex Health with a new price target

      Maxim Group initiated coverage of Nutex Health with a rating of Buy and set a new price target of $45.00

      9/18/24 8:12:45 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Northland Capital initiated coverage on Nutex Health with a new price target

      Northland Capital initiated coverage of Nutex Health with a rating of Outperform and set a new price target of $3.00

      2/22/23 9:08:40 AM ET
      $NUTX
      Business Services
      Consumer Discretionary

    $NUTX
    Leadership Updates

    Live Leadership Updates

    See more
    • NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF GRANT THORNTON LLP AS ITS INDEPENDENT AUDITOR

      HOUSTON, May 22, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Grant Thornton LLP ("Grant Thornton") as the Company's independent registered public accounting firm to replace CBIZ CPAs ("CBIZ"), effective May 15, 2025. The change of the Company's independent auditor was made after careful consideration and an evaluation process and was approved by the Audit Committee and the Board of Directors of the

      5/22/25 6:30:00 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • NUTEX HEALTH ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS

      HOUSTON, April 22, 2024 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 21 state-of-the-art micro hospitals in 9 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Scott J. Saunders, and Kelvin Spears, MD, to its Board of Directors.  They replace John Waters, who recently passed away, and Dr. Daniel Stites, who fulfilled his one-year term Board commitment. The Board has determined that Mr. Saunders satisfies the current independent director standards established by the rules of The Nasdaq Stock Market. Mr. Saunders will s

      4/22/24 5:30:00 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF JOSHUA DETILLIO AS ITS NEW CHIEF OPERATING OFFICER

      HOUSTON, Sept. 5, 2023 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 22 state-of-the-art micro hospitals in 8 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Joshua DeTillio as the Company's Chief Operating Officer effective on or about October 2, 2023. Mr. DeTillio is an experienced healthcare leader with over 20 years of hospital experience and 12 years as a CEO in investor-owned, publicly traded companies. He has demonstrated success in collaborating with and leading boards and physicians to drive growth, improve c

      9/5/23 5:30:00 AM ET
      $NUTX
      Business Services
      Consumer Discretionary

    $NUTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Bates Jon Christian converted options into 1,611 shares and bought $81,810 worth of shares (1,000 units at $81.81), increasing direct ownership by 115% to 4,888 units (SEC Form 4)

      4 - Nutex Health, Inc. (0001479681) (Issuer)

      4/14/25 4:30:48 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Chief Financial Officer Bates Jon Christian bought $28,970 worth of shares (1,350 units at $21.46), increasing direct ownership by 146% to 2,277 units (SEC Form 4)

      4 - Nutex Health, Inc. (0001479681) (Issuer)

      8/26/24 11:54:30 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Chief Operating Officer Detillio Joshua bought $10,800 worth of shares (20,000 units at $0.54), increasing direct ownership by 214% to 29,333 units (SEC Form 4)

      4 - Nutex Health, Inc. (0001479681) (Issuer)

      6/13/24 11:50:03 AM ET
      $NUTX
      Business Services
      Consumer Discretionary

    $NUTX
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Nutex Health Inc.

      DEFA14A - Nutex Health, Inc. (0001479681) (Filer)

      6/3/25 5:20:57 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • SEC Form DEFA14A filed by Nutex Health Inc.

      DEFA14A - Nutex Health, Inc. (0001479681) (Filer)

      6/2/25 5:02:46 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • SEC Form DEF 14A filed by Nutex Health Inc.

      DEF 14A - Nutex Health, Inc. (0001479681) (Filer)

      6/2/25 5:00:07 PM ET
      $NUTX
      Business Services
      Consumer Discretionary

    $NUTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Nutex Health Inc.

      SC 13G - Nutex Health, Inc. (0001479681) (Subject)

      11/14/24 11:02:17 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Nutex Health Inc. (Amendment)

      SC 13G/A - Nutex Health, Inc. (0001479681) (Subject)

      9/26/23 4:26:07 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • SEC Form SC 13G filed by Nutex Health Inc.

      SC 13G - Nutex Health, Inc. (0001479681) (Subject)

      7/7/23 5:03:39 PM ET
      $NUTX
      Business Services
      Consumer Discretionary

    $NUTX
    Financials

    Live finance-specific insights

    See more
    • Nutex Health Schedules 2025 First Quarter Financial Results Release and Conference Call

      HOUSTON, May 7, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals in 11 states and primary care-centric, risk-bearing physician networks, today announced that it will release financial results for the first quarter ended March 31, 2025 after the close of the stock market on Tuesday, May 13, 2025. The Company will discuss those results on a conference call on Wednesday, May 14, 2025, at 10:30 a.m. ET. Participant Listening: 1-877-407-9208 or 1-201-493-6784 Participant Link: https://callme.viavid.com/viavid/?callme=true&passcode=13746493&h=true&info=com

      5/7/25 6:30:00 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • NUTEX HEALTH SCHEDULES 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS RELEASE AND CONFERENCE CALL

      HOUSTON, March 17, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals in 11 states and primary care-centric, risk-bearing physician networks, today announced that it will release financial results for the fourth quarter and year ended December 31, 2024 after the close of the stock market on March 27th, 2025. The Company will discuss those results on a conference call on Friday, March 28st, 2025, at 10:30 am ET. Participant Listening: 1-877-407-9208 or 1-201-493-6784 Participant Link: https://viavid.webcasts.com/starthere.jsp?ei=1706653&tp_key=5e3e4c2f6

      3/17/25 5:30:00 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • NUTEX HEALTH SCHEDULES 2024 THIRD QUARTER FINANCIAL RESULTS RELEASE AND CONFERENCE CALL

      HOUSTON, Nov. 5, 2024 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 22 state-of-the-art micro hospitals in 10 states and primary care-centric, risk-bearing physician networks, today announced that it will release financial results for the third quarter ended September 30, 2024 after the close of the stock market on Thursday, November 7, 2024. The Company will discuss those results on a conference call on Friday, November 8, 2024, at 10:30 am ET. Participant Listening: 1-877-407-9208 or 1-201-493-6784 Participant webcast: https://viavid.webcasts.com/starthere.jsp?ei=1691722&tp_key=bfd69ce

      11/5/24 5:30:00 AM ET
      $NUTX
      Business Services
      Consumer Discretionary